Reddit proved business resilience supported by strong execution capability. Advertising revenue and ARPU are growing rapidly, with fast EBITDA margin improving toward industry-leading levels. Valuation is attractive, with a projected 30% revenue CAGR and strong capital returns justifying a premium, and a target price of $255 is set.

image for news Reddit: Business Resilience Undervalued, Healthy Consolidation Creates A Buying Opportunity

Can CleanSpark's Data Center Push Unlock New AI Revenue Streams? — Positive

CLSK   Zacks Investment Research — November 19, 2025

CLSK pivots from pure Bitcoin mining to build AI-ready data centers, aiming to unlock long-term growth through diversified digital infrastructure.

image for news Can CleanSpark's Data Center Push Unlock New AI Revenue Streams?

Lumen and Meter Launch AI-Driven WAN-to-LAN Solution for Enterprises — Positive

LUMN   Zacks Investment Research — November 19, 2025

LUMN's collaboration with Meter debuts a unified WAN-to-LAN solution built to simplify AI-ready enterprise connectivity and operations.

image for news Lumen and Meter Launch AI-Driven WAN-to-LAN Solution for Enterprises

Is Percipio the Key to Reshaping Skillsoft's Market Positioning? — Positive

SKIL   Zacks Investment Research — November 19, 2025

SKIL's Percipio drives soaring AI learning adoption and major workforce wins, strengthening its position in the evolving upskilling market.

image for news Is Percipio the Key to Reshaping Skillsoft's Market Positioning?

Gladstone Capital: The BDC Is Back On The Growth Track, It's A Buy — Positive

GLAD   Seeking Alpha — November 19, 2025

Gladstone Capital has been one of my equity-focused BDC picks, which as opposed to FDUS and TRIN has delivered unpleasant returns. Recently, GLAD announced a dividend cut, which also came as a surprise to me. Yet, the Q4 2025 data points, in my view, indicate a clear turning point.

image for news Gladstone Capital: The BDC Is Back On The Growth Track, It's A Buy

MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its submission entitled “Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study” has been selected for a poster presentation at the 18th Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) to be held December 1-4, 2025 in San Diego, CA. “We are excited to have been selected to present important laromestrocel data at this leading forum for Alzheimer's research and clinical investigation,” said Joshua …

image for news Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

AUSTIN, Texas, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) today announced that its Board of Directors has initiated a review of strategic alternatives in order to explore ways to maximize shareholder value. The review will include a range of potential actions, including raising equity capital, reverse mergers, combination transactions, and the sale of all or part of the Company's business, and other possible strategic or financial transactions.

image for news Astrotech Announces Review of Strategic Alternatives to Maximize Shareholder Value

SAN DIEGO , Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its Managed Access Program (MAP) for investigational therapy delpacibart zotadirsen (del-zota) for eligible people with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44) in the United States. "We recognize the considerable needs facing the DMD44 community given there are no approved exon skipping therapies for this disease as well as the potential of del-zota based on the unprecedented data shown in our clinical studies," said Sarah …

image for news Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

Nvidia stock price has pulled back in the past two weeks, moving from the year-to-date high of $212 to $180. This retreat will either accelerate or reverse once the company publishes its financial results later today.

image for news Nvidia stock price forecast: NVDA is extremely cheap ahead of earnings

New York, New York--(Newsfile Corp. - November 19, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=178166&wire=5&utm_campaign=12 or contact Joseph E. Levi, Esq.

image for news Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action

Actelis Networks Secures New Order for Leading Japanese Railway Operator — Neutral

ASNS   GlobeNewsWire — November 19, 2025

Nearly $100,000 order demonstrates growing adoption of Actelis' networking solutions in Japan's rail sector Nearly $100,000 order demonstrates growing adoption of Actelis' networking solutions in Japan's rail sector

image for news Actelis Networks Secures New Order for Leading Japanese Railway Operator

Rigetti: Quantum Infrastructure Cornerstone In The Making — Positive

RGTI   Seeking Alpha — November 19, 2025

Rigetti Computing (RGTI) remains a 'Buy' due to its accelerated technology roadmap, commercial wins, and strong strategic positioning in quantum computing. RGTI's modular chiplet architecture and ambitious milestones, including a 1,000+ qubit system by 2027, differentiate it from competitors and add credibility. Recent commercial wins, including contracts with AFRL and partnerships with Nvidia, validate RGTI's technology and expand its growth opportunities.

image for news Rigetti: Quantum Infrastructure Cornerstone In The Making

M2i Global Inc (OTC:MTWO) and Volato Group have signed a memorandum of understanding (MOU) with Nimy Resources to pursue a supply agreement for gallium sourced from Western Australia, the companies announced on Wednesday. Under the non-binding MOU, Nimy and M2i plan to work toward commercially binding terms for the sale and purchase of gallium from Nimy's Mons Project.

image for news M2i Global, Volato Group sign MOU with Nimy Resources for access to Western Australia gallium

WIX's Q3 Earnings & Revenues Top, Increase Y/Y on Base44 Momentum — Positive

WIX   Zacks Investment Research — November 19, 2025

WIX posts Q3 beat as 14% revenue growth and surging Base44 adoption push the company to raise full-year bookings and revenue guidance.

image for news WIX's Q3 Earnings & Revenues Top, Increase Y/Y on Base44 Momentum

Valvoline (VVV) Q4 Earnings and Revenues Miss Estimates — Negative

VVV   Zacks Investment Research — November 19, 2025

Valvoline (VVV) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.46 per share a year ago.

image for news Valvoline (VVV) Q4 Earnings and Revenues Miss Estimates

Viking Holdings (VIK) Q3 Earnings and Revenues Top Estimates — Positive

VIK   Zacks Investment Research — November 19, 2025

Viking Holdings (VIK) came out with quarterly earnings of $1.2 per share, beating the Zacks Consensus Estimate of $1.19 per share. This compares to earnings of $0.89 per share a year ago.

image for news Viking Holdings (VIK) Q3 Earnings and Revenues Top Estimates

Not for distribution to U.S. news wire services or dissemination in the United States. THE BASE SHELF PROSPECTUS IS ACCESSIBLE, AND THE SHELF PROSPECTUS SUPPLEMENT FOR THE PUBLIC OFFERING AND ANY AMENDMENT TO THE DOCUMENTS WILL BE ACCESSIBLE, WITHIN TWO BUSINESS DAYS, THROUGH SEDAR+ BROOKFIELD, NEWS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Brookfield Corporation (“Brookfield”) (NYSE: BN, TSX: BN) today announced that it has agreed to issue 8,000,000 Class A Preference Shares, Series 54 (“Preferred Shares, Series 54”) on a bought deal basis to a syndicate of underwriters (the “Underwriters”) led by Scotiabank, BMO Capital Markets, CIBC Capital Markets, National …

image for news Brookfield Corporation to Issue C$200 Million of Preferred Shares and Redeem a Minimum of C$200 Million of its Class A Preference Shares, Series 44

Can a single stock take down the whole market? Here's what to know ahead of Nvidia's critical earnings.

image for news Can a single stock take down the whole market? What to know ahead of Nvidia's critical earnings

Key Takeaways

image for news Markets Stumble As Fed Signals, Earnings, And AI Crosscurrents Drive Volatility

What's The Downside Risk For META Stock Amid AI Bubble — Negative

META   Forbes — November 19, 2025

META Platforms stock (NASDAQ: META) has declined by 18.4% within a span of 21 trading days. This significant drop indicates renewed worries among investors concerning the company's aggressive expenditure on both AI infrastructure and its Reality Labs division.

image for news What's The Downside Risk For META Stock Amid AI Bubble